CKD-828 S-Amlodipine Non-Responder Trial
Primary Purpose
Hypertension
Status
Completed
Phase
Phase 3
Locations
Korea, Republic of
Study Type
Interventional
Intervention
CKD-828 2.5/40mg
CKD-828 2.5/80mg
S-Amlodipine 2.5mg
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension focused on measuring CKD-828, Hypertension, Primary Hypertension, S-Amlodipine, Telmisartan, Non-Responder
Eligibility Criteria
Inclusion Criteria:
- age 18 years or older
- diagnosis of essential hypertension and blood pressure not adequately controlled (inadequate control defined as seated diastolic blood pressure(DBP)≥ 90mmHg if on existing amtihypertensive treatment of seated DBP≥100mmHg if treatment naive)
- failure to respond to four weeks treatment with S-Amlodipine 2.5mg(failure to respond defined as seated DBP ≥ 90mmHg)
- willing and able to provide written informed consent
Exclusion Criteria:
- mean seated DBP ≥ 120mmHg and/or mean seated SBP ≥ 200mmHg during run-in treatment or mean seated DBP ≥ 120mmHg and/or mean seated SBP ≥ 180mmHg at the randomization visit
- known or suspected secondary hypertension(ex. aortic coarctation, Primary hyperaldosteronism, renal artery stenosis, pheochromocytoma)
- has severe heart disease(Heart failure NYHA functional class 3, 4), unstable angina or myocardial infarction, arrhythmia within the past three months
- has cerebrovascular disease as cerebral infarction, cerebral hemorrhage within 6 months
- Type I Diabetes Mellitus, Type II Diabetes Mellitus with poor glucose control as defined by fasting glucosylated hemoglobin(HbA1c) > 8%
- known severe or malignant retinopathy
- hepatic or renal dysfunction as defined by the following laboratory parameters: AST/ALT > UNL X 2, serum creatinine > UNL X 1.5
- acute or chronic inflammatory status need to treatment
- need to additional antihypertensive drugs during the study
- need to concomitant medications known to affect blood pressure during the study
- history of angioedema related to ACE inhibitors or Angiotensin II Receptor Blockers
- known hypersensitivity related to either study drug
- history of drug or alcohol dependency within 6 months
- any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of investigational products(ex. gastrointestinal tract surgery such as gastrectomy, gastroenterostomy or bypass, active inflammatory bowel syndrome within 12 months prior to screening, gastric ulcers need to treatment, gastrointestinal/rectal bleeding, impaired pancreatic function such as pancreatitis, obstructions of the urinary tract or difficulty in voiding
- administration of other study drugs within 30 days prior to randomization
- premenopausal women(last menstruation < 1year) not using adequate contraception, pregnant or breast-feeding
- history of malignancy including leukemia and lymphoma within the past 5 years
- in investigator's judgment
Sites / Locations
- Seoul St. Mary's hospital, The catholic university of Korea
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Active Comparator
Arm Label
CKD-828 2.5/40mg
CKD-828 2.5/80mg
S-Amlodipine 2.5mg
Arm Description
CKD-828 2.5/40mg
CKD-828 2.5/80mg
S-Amlodipine 2.5mg
Outcomes
Primary Outcome Measures
Mean Sitting Diastolic Blood Pressure (MSDBP)
Secondary Outcome Measures
Mean Sitting Diastolic Blood Pressure (MSDBP)
Mean Sitting Systolic Blood Pressure (MSSBP)
Control Rate
SBP<140mmHg, DBP<90mmHg
Response Rate
Reduction of SBP≥20mmHg, DBP≥10mmHg
Full Information
NCT ID
NCT01501253
First Posted
December 26, 2011
Last Updated
November 12, 2012
Sponsor
Chong Kun Dang Pharmaceutical
1. Study Identification
Unique Protocol Identification Number
NCT01501253
Brief Title
CKD-828 S-Amlodipine Non-Responder Trial
Official Title
Evaluate the Efficacy and Safety of a Fixed Dose Combination of S-Amlodipine and Telmisartan(CKD-828) vs. S-Amlodipine Monotherapy in Hypertensive Patients Inadequately Controlled by S-Amlodipine Monotherapy.
Study Type
Interventional
2. Study Status
Record Verification Date
November 2012
Overall Recruitment Status
Completed
Study Start Date
August 2011 (undefined)
Primary Completion Date
September 2012 (Actual)
Study Completion Date
September 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Chong Kun Dang Pharmaceutical
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The aim of present study is to evaluate the efficacy and safety of two dose combination of S-Amlodipine/Telmisartan (2.5/40mg amd 2.5/80mg) compared with S-Amlodipine monotherapy (2.5mg) in hypertensive patients inadequately controlled by S-Amlodipine monotherapy.
Detailed Description
In patients with essential hypertension inadequately controlled by S-Amlodipine monotherapy to evaluate the efficacy and safety of two dose combination of S-Amlodipine/Telmisartan (2.5/40mg amd 2.5/80mg) compared with S-Amlodipine monotherapy (2.5mg)during 8weeks.
Included S-Amlodipine run-in period(during 4 weeks_single blind) and Treatment period(during 8 weeks_double blind).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
CKD-828, Hypertension, Primary Hypertension, S-Amlodipine, Telmisartan, Non-Responder
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
187 (Actual)
8. Arms, Groups, and Interventions
Arm Title
CKD-828 2.5/40mg
Arm Type
Experimental
Arm Description
CKD-828 2.5/40mg
Arm Title
CKD-828 2.5/80mg
Arm Type
Experimental
Arm Description
CKD-828 2.5/80mg
Arm Title
S-Amlodipine 2.5mg
Arm Type
Active Comparator
Arm Description
S-Amlodipine 2.5mg
Intervention Type
Drug
Intervention Name(s)
CKD-828 2.5/40mg
Intervention Description
fixed dose combination of S-Amlodipine 2.5mg and Telmisartan 40mg
Intervention Type
Drug
Intervention Name(s)
CKD-828 2.5/80mg
Intervention Description
Fixed dose combination of S-Amlodipine 2.5 and Telmisartan 80mg
Intervention Type
Drug
Intervention Name(s)
S-Amlodipine 2.5mg
Other Intervention Name(s)
Anydipine S tab.
Intervention Description
S-Amlodipine 2.5mg monotherapy
Primary Outcome Measure Information:
Title
Mean Sitting Diastolic Blood Pressure (MSDBP)
Time Frame
After 8 weeks of treatment
Secondary Outcome Measure Information:
Title
Mean Sitting Diastolic Blood Pressure (MSDBP)
Time Frame
After 4 weeks of treatment
Title
Mean Sitting Systolic Blood Pressure (MSSBP)
Time Frame
After 4 weeks and 8 weeks of treatment
Title
Control Rate
Description
SBP<140mmHg, DBP<90mmHg
Time Frame
After 8 weeks of treatment
Title
Response Rate
Description
Reduction of SBP≥20mmHg, DBP≥10mmHg
Time Frame
After 8 weeks of treatment
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
age 18 years or older
diagnosis of essential hypertension and blood pressure not adequately controlled (inadequate control defined as seated diastolic blood pressure(DBP)≥ 90mmHg if on existing amtihypertensive treatment of seated DBP≥100mmHg if treatment naive)
failure to respond to four weeks treatment with S-Amlodipine 2.5mg(failure to respond defined as seated DBP ≥ 90mmHg)
willing and able to provide written informed consent
Exclusion Criteria:
mean seated DBP ≥ 120mmHg and/or mean seated SBP ≥ 200mmHg during run-in treatment or mean seated DBP ≥ 120mmHg and/or mean seated SBP ≥ 180mmHg at the randomization visit
known or suspected secondary hypertension(ex. aortic coarctation, Primary hyperaldosteronism, renal artery stenosis, pheochromocytoma)
has severe heart disease(Heart failure NYHA functional class 3, 4), unstable angina or myocardial infarction, arrhythmia within the past three months
has cerebrovascular disease as cerebral infarction, cerebral hemorrhage within 6 months
Type I Diabetes Mellitus, Type II Diabetes Mellitus with poor glucose control as defined by fasting glucosylated hemoglobin(HbA1c) > 8%
known severe or malignant retinopathy
hepatic or renal dysfunction as defined by the following laboratory parameters: AST/ALT > UNL X 2, serum creatinine > UNL X 1.5
acute or chronic inflammatory status need to treatment
need to additional antihypertensive drugs during the study
need to concomitant medications known to affect blood pressure during the study
history of angioedema related to ACE inhibitors or Angiotensin II Receptor Blockers
known hypersensitivity related to either study drug
history of drug or alcohol dependency within 6 months
any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of investigational products(ex. gastrointestinal tract surgery such as gastrectomy, gastroenterostomy or bypass, active inflammatory bowel syndrome within 12 months prior to screening, gastric ulcers need to treatment, gastrointestinal/rectal bleeding, impaired pancreatic function such as pancreatitis, obstructions of the urinary tract or difficulty in voiding
administration of other study drugs within 30 days prior to randomization
premenopausal women(last menstruation < 1year) not using adequate contraception, pregnant or breast-feeding
history of malignancy including leukemia and lymphoma within the past 5 years
in investigator's judgment
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ho-Joong Yoon, Ph.D
Organizational Affiliation
Seoul St. Mary's hospital, The catholic university of Korea
Official's Role
Principal Investigator
Facility Information:
Facility Name
Seoul St. Mary's hospital, The catholic university of Korea
City
Seoul
Country
Korea, Republic of
12. IPD Sharing Statement
Learn more about this trial
CKD-828 S-Amlodipine Non-Responder Trial
We'll reach out to this number within 24 hrs